1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 1:Clinical characteristics of the patientsa
Characteristics Total 67 Age (yr) 53 (SD, 12) No. of female patients 28 (42) Functioning adenoma 14 (21) Prolactin 5 (7.5) Growth hormone 7 (10) Adrenocorticotropic hormone 1 (1.5) Thyroid stimulating hormone 1 (1.5) CS invasion by reference standard 29 (43) Residual tumor following operation determined by follow-up MR imaging 11 (16) Postoperative stereotactic radiation therapy 7 (10)
Note:—CS indicates cavernous sinus.
↵a Data are expressed as the mean (SD) or numbers with percentages in parenthesis.